ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,712,158 | +24.8% | 431,546 | +41.3% | 0.05% | +31.6% |
| Q2 2023 | $9,386,951 | -52.3% | 305,366 | -44.1% | 0.04% | -56.3% |
| Q1 2023 | $19,698,826 | +87.2% | 546,734 | +105.3% | 0.09% | +70.6% |
| Q4 2022 | $10,524,136 | +55.8% | 266,299 | +58.3% | 0.05% | +45.7% |
| Q3 2022 | $6,757,000 | -36.5% | 168,173 | -33.6% | 0.04% | -32.7% |
| Q2 2022 | $10,647,000 | -7.2% | 253,266 | -14.0% | 0.05% | +15.6% |
| Q1 2022 | $11,470,000 | +57.9% | 294,399 | +61.5% | 0.04% | +66.7% |
| Q4 2021 | $7,266,000 | -41.0% | 182,331 | -46.5% | 0.03% | -51.8% |
| Q3 2021 | $12,323,000 | -69.0% | 340,979 | -64.8% | 0.06% | -68.0% |
| Q2 2021 | $39,761,000 | +2.4% | 970,006 | +9.0% | 0.18% | -0.6% |
| Q1 2021 | $38,811,000 | +196.9% | 889,751 | +240.7% | 0.18% | +214.3% |
| Q4 2020 | $13,070,000 | – | 261,145 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |